Merck announced yesterday the creation of a nonprofit biomedical research institution for translational medicine, focused on the discovery of innovative, new medicines to treat disease. The institute, called the California Institute for Biomedical Research (Calibr), is located in San Diego and will work collaboratively with academic scientists to advance discoveries to preclinical proof of concept, at which point a commercialization partner will be sought. Merck has the option to license any therapeutic candidates that result from research conducted.
Leading the institute is Peter G. Schultz, Ph.D, a renowned chemist at The Scripps Research Institute and serial biotechnology entrepreneur who has founded companies such as Affymax Research Institute, Syrrx, Kalypsys, Phenomix, Symyx Therapeutics, Ilypsa, Wildcat Technologies and Ambrx.
Ambrx is a client of Russo Partners, and we are currently focused on raising awareness of the company’s antibody drug conjugate (ADC) program, which utilizes the company’s protein medicinal chemistry technology to create best-in-class ADCs.
Merck will invest $90 million into the new institute over the next seven years, during which 150 employees will be hired. Key academic institutions in the area include The Scripps Research Institute, The Salk Institute, University of California, San Diego and Sanford-Burnham Medical Research Institute.
Read more about the new institute in the following articles from Xconomy and the San Diego Union-Tribune:
San Diego Union-Tribune
Posted in Uncategorized
Tagged Ambrx, Biomedical research, California Institute for Biomedical Research, Merck, Peter Schultz, pharma, Salk institute, San Diego, Sanford-Burnham Medical Research Institute, The Scripps Research Institute, Translational research
If you totaled the number of extra pounds each person in our country weighs, as a whole our nation is 5 billion pounds overweight. It is clear that diet and exercise are not enough to combat the growing epidemic of obesity. Innovative therapeutics and technologies must be developed and pursed in order to treat the numbers of people affected by this condition.
In recognition of this need, obesity was a hot topic this week, as multiple events discussing the use of therapeutics to control this indication were held around the nation.
In New York, a world-renowned authority on hormones, Ronald M. Evans, Ph.D., spoke at a NY Salkexcellerators event about the availability of drugs that could simulate the effect of exercise and reduce muscle wasting. When he is not busy conducting research at the Salk institute about hormones and their functions in normal activities and disease, Dr. Evans enjoys spending time with his daughter, Russo Partners team member Lena Evans.
Further down the coast in Orlando, our client Arena Pharmaceuticals presented at The Obesity Society’s Annual Scientific Meeting. One of the world’s largest gatherings of obesity professionals, leading obesity scientists and clinicians were in attendance to discuss new research findings to help promote treatments for patients with this disease.
With the levels of obesity in our nation growing, we are glad to see that research and therapeutics are under development to help combat the increasing incidence of this disease.